Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2025-12-12 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞关于对外捐赠的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding an external donation plan for the year 2026. It details the board meeting approval, the purpose of the donation, the impact on the company, and the need for shareholder approval. The document is short (1307 characters), does not contain financial statements or detailed financial data, and is not a report but an announcement of a corporate action related to social responsibility and charitable donations. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a regulatory filing or certification either. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2025-12-12 Chinese
神州细胞关于2025年度向特定对象发行A股股票申请收到上海证券交易所审核意见通知的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding the receipt of the Shanghai Stock Exchange's review opinion on the company's application for a specific issuance of A-shares in 2025. It mentions the approval process and the need for further registration approval from the China Securities Regulatory Commission. The document is short (557 characters) and serves as a formal notification about the status of a capital raising activity, specifically a share issuance. It does not contain financial statements or detailed financial data, nor is it a full report. Therefore, it fits the category of a Capital/Financing Update (CAP).
2025-12-05 Chinese
神州细胞关于召开2025年第三季度业绩说明会的公告
Regulatory Filings Classification · 90% confidence The document is an announcement about the upcoming 2025 third quarter earnings explanation meeting (业绩说明会) for Beijing Sinocell Technology Group Co., Ltd. It specifies the date, time, format (online text interaction), and participation details for the meeting. It references that the 2025 Q3 report has already been disclosed on the Shanghai Stock Exchange website. The document does not contain actual financial data or detailed financial analysis but serves to inform investors about the event where the company will discuss the Q3 results. This matches the definition of a Call Transcript (CT) type document, specifically an earnings call or earnings explanation meeting announcement. However, since it is only an announcement of the meeting and not the transcript itself, and given the short length (1551 characters), it is best classified as a Regulatory Filing (RNS) because it does not contain the transcript or detailed financial data but is an official regulatory announcement about the earnings call event. Therefore, the filing type is RNS with high confidence.
2025-11-07 Chinese
神州细胞2025年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '北京神州细胞生物技术集团股份公司 2025 年第三季度报告' which translates to 'Beijing Shenzhou Cell Biotechnology Group Co., Ltd. 2025 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the third quarter of 2025. The report includes unaudited financial statements and management assurances about the accuracy and completeness of the report. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (quarterly) clearly identifies this as an Interim / Quarterly Report. The document length (13,076 characters) and detailed financial content confirm it is the report itself, not just an announcement or summary. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). 9M 2025
2025-10-30 Chinese
北京市金杜律师事务所关于北京神州细胞生物技术集团股份公司2025年度向特定对象发行A股股票的补充法律意见书（二）
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a company's 2025 planned private placement of A shares. It discusses the legal compliance, funding sources, financing arrangements, and regulatory requirements related to the issuance. The document references specific regulatory rules and provides a thorough legal review of the issuance process. It is not a financial report, earnings release, or management discussion, but a legal opinion related to a capital raising event. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2025-10-14 Chinese
关于北京神州细胞生物技术集团股份公司2025年度向特定对象发行A股股票申请文件的审核问询函的回复报告
Capital/Financing Update Classification · 95% confidence The document is a detailed reply report to an inquiry letter from the Shanghai Stock Exchange regarding a company's application for a specific issuance of A shares to particular investors. It includes extensive information about the issuance purpose, funding sources, financial arrangements, shareholder meetings, stock price analysis, compliance with regulatory rules, and shareholder lock-up and reduction details. The content focuses on the company's capital raising activities, financing plans, and regulatory compliance related to a specific share issuance. There is no indication that this is a full annual or quarterly report, audit report, earnings release, or other types of filings. The document is clearly related to capital raising and financing updates. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed financial and procedural information support this classification with high confidence.
2025-10-14 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.